World Equity Group Inc. Makes New Investment in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

World Equity Group Inc. bought a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 20,000 shares of the biotechnology company’s stock, valued at approximately $48,000.

Several other large investors have also added to or reduced their stakes in the stock. Peapod Lane Capital LLC bought a new stake in shares of Oramed Pharmaceuticals during the 4th quarter valued at about $550,000. Marquette Asset Management LLC bought a new stake in shares of Oramed Pharmaceuticals during the 4th quarter valued at about $81,000. XTX Topco Ltd boosted its position in shares of Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 9,242 shares during the last quarter. Murchinson Ltd. boosted its position in shares of Oramed Pharmaceuticals by 0.5% during the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock valued at $4,170,000 after acquiring an additional 8,889 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Oramed Pharmaceuticals during the 3rd quarter valued at about $272,000. Institutional investors own 12.73% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com downgraded Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 19th.

Oramed Pharmaceuticals Trading Up 0.5 %

Shares of ORMP opened at $2.16 on Tuesday. The company has a market cap of $87.07 million, a PE ratio of 19.64 and a beta of 1.66. Oramed Pharmaceuticals Inc. has a 12-month low of $2.00 and a 12-month high of $3.67. The stock has a 50-day moving average price of $2.33 and a 200-day moving average price of $2.36.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.